- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, Lymphodepletion Therapy
- Biological · Procedure · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 2,480
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Diseases
- Interventions
- RSV Vaccine, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 5,815 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
- Interventions
- Olaparib, ASTX727
- Drug
- Lead sponsor
- Varun Monga, MBBS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib, Amivantamab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 701 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 12 more
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
- Drug
- Lead sponsor
- Adagene Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Interventions
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Rivoceranib, Trifluridine/Tipiracil
- Drug
- Lead sponsor
- Elevar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Chicago, Illinois • St Louis, Missouri + 1 more
- Conditions
- Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Interventions
- Rapidly generated virus specific T (R-MVST) cells
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Selumetinib, Pembrolizumab
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more
- Conditions
- Gastric Cancer
- Interventions
- Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, Cisplatin, Pembrolizumab, Volrustomig, Rilvegostomig
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
- Interventions
- AZD0120
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Francisco, California • Tampa, Florida + 7 more
- Conditions
- Solid Tumors
- Interventions
- Tislelizumab, Pamiparib
- Biological · Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
- Drug · Procedure · Other
- Lead sponsor
- Jeffrey Gelfand
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
- Interventions
- VRx-3996 and valganciclovir
- Combination Product
- Lead sponsor
- Viracta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 15 more
- Conditions
- Lung Cancer
- Interventions
- TRC105
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Interventions
- JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Atlanta, Georgia
- Conditions
- Myasthenia Gravis
- Interventions
- IM-101 Part A, Placebo Part A, IM-101 Part B, Placebo Part B
- Drug
- Lead sponsor
- ImmunAbs Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Altamonte Springs, Florida • Boca Raton, Florida • Naples, Florida + 4 more
- Conditions
- Endometrial Cancer, Ovarian Cancer
- Interventions
- Ridaforolimus, Paclitaxel, carboplatin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Parkinson's Disease
- Interventions
- PF-06412562, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 5
- States / cities
- Aventura, Florida • Baco Raton, Florida • South Miami, Florida + 2 more
- Conditions
- Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
- Interventions
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
- Drug
- Lead sponsor
- Innoviva Specialty Therapeutics
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more
- Conditions
- Tumors
- Interventions
- Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 50
- States / cities
- Anchorage, Alaska • Oro Valley, Arizona • Tucson, Arizona + 34 more
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
- Conditions
- Ricin Poisoning
- Interventions
- RVEc
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fort Deterick, Maryland
- Conditions
- Extramedullary Disease in Multiple Myeloma, Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, External Beam Radiation Therapy, Image Guided Biopsy, Positron Emission Tomography, Talquetamab
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Duarte, California